



Embarrassment and Shame in People With Parkinson's Disease: A New Tool for Self-Assessment

Vanessa Fleury^{1,2*}, Sabina Catalano Chiuve², Maria João Forjaz^{3,4}, Mariagrazia Di Marco⁵, Maria Messe², Ines Debove⁶, Julio Angulo^{7,8,9}, Gun-Marie Hariz¹⁰, Pierre R. Burkhard^{1,2}, Pablo Martinez-Martin⁴, Carmen Rodriguez-Blazquez^{3,4} and Paul Krack⁶

¹ Faculty of Medicine, University of Geneva, Geneva, Switzerland, ² Division of Neurology, Geneva University Hospitals, Geneva, Switzerland, ³ National Centre of Epidemiology, Carlos III Institute of Health, REDISSEC, Madrid, Spain, ⁴ Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain, ⁵ Clinical Investigation Unit, Geneva University Hospitals, Geneva, Switzerland, ⁶ Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland, ⁷ Morningview Place, Lake Oswego, OR, United States, ⁸ Member, Persons With Parkinson's Advisory Council, Parkinson Foundation, Miami, FL, United States, ⁹ Member, Program Design Committee 2019 World Parkinson's Congress, World Parkinson's Coalition, New York, NY, United States, ¹⁰ Department of Clinical Science, Neuroscience, Umeå University, Umeå, Sweden

OPEN ACCESS

Edited by:

Tim Anderson,
University of Otago, Christchurch,
New Zealand

Reviewed by:

Simon J. G. Lewis,
Brain and Mind Research Institute,
Australia

Chien Tai Hong,

Taipei Medical University, Taiwan

*Correspondence:

Vanessa Fleury
Vanessa.FleuryNissen@hcuge.ch

Specialty section:

This article was submitted to
Movement Disorders,
a section of the journal
Frontiers in Neurology

Received: 22 April 2020

Accepted: 24 June 2020

Published: 31 July 2020

Citation:

Fleury V, Catalano Chiuve S,
Forjaz MJ, Di Marco M, Messe M,
Debove I, Angulo J, Hariz G-M,
Burkhard PR, Martinez-Martin P,
Rodriguez-Blazquez C and Krack P
(2020) Embarrassment and Shame in
People With Parkinson's Disease: A
New Tool for Self-Assessment.
Front. Neurol. 11:779.
doi: 10.3389/fneur.2020.00779

Shame and embarrassment related to Parkinson's disease (PD) are rarely addressed in clinical practice nor studied in neuroscience research, partly because no specific tool exists to detect them in PD.

Objective: To develop a self-applied assessment tool of shame and embarrassment specifically related to PD or its treatment, to promptly identify the presence and severity of these two emotions in PD.

Methods: Identification and selection of relevant items were obtained from the collection of PD patients' opinions during support groups and interviews. Several further items were added following a literature review. Subsequently, a two-phase pilot study was performed for identification of ambiguous items and omissions, and to obtain preliminary data on acceptability, reliability, validity and relevance of the new scale (SPARK).

Results: A total of 105 PD patients were enrolled in the study. Embarrassment was reported in 85% of patients, while shame was present in 26%. Fifteen percent of patients did not describe any shame or embarrassment. On average, the intensity of these two emotions was low with a marked floor effect in SPARK items and subscales. However, SPARK total score inter-individual variability was important (range 1–84 out of 99). Acceptability and quality of data were satisfactory with no floor or ceiling effects (2.9% each) or missing data. Internal consistency (Cronbach's alpha) was 0.94 for total score and 0.73–0.87 for subscales. The scale correlated ≥ 0.60 with instruments measuring related constructs. Content validity was satisfactory. SPARK total score strongly correlated with impaired health-related quality of life ($r_S = 0.81$), the propensity to feel embarrassed or ashamed ($r_S = 0.68$ and 0.66 , respectively), and anxiety ($r_S = 0.72$) and depression ($r_S = 0.63$) levels. Moderate to high correlations were observed between SPARK total score and apathy ($r_S = 0.46$) and a more pronounced personality trait directed toward harm avoidance ($r_S = 0.46$). No significant differences in SPARK

scores were found by sex, education level, PD duration, Hoehn and Yahr stages or PD phenotype.

Conclusion: Preliminary analysis of psychometric properties suggests that SPARK could be an acceptable and reliable instrument for assessing shame and embarrassment in PD. SPARK could help healthcare professionals to identify and characterize PD-induced shame and embarrassment.

Keywords: parkinson's disease, shame, embarrassment, questionnaire, non-motor symptoms

INTRODUCTION

Patients affected with Parkinson's disease (PD) perceive non-motor symptoms as serious challenges and barriers to a satisfying quality of life (1). PD-related shame and embarrassment are rarely addressed in clinical practice nor studied in neuroscience research (2). The prevalence of shame and embarrassment in PD is unknown and no specific tool exists to detect and measure them in PD.

Shame and embarrassment are two negative self-conscious emotions associated with painful states, where the self (i.e., the affective representation of one's identity) is focal in attention. The individual believes that she/he has failed to meet appropriate standards of conduct, and thinks that she/he has done so in the eyes of others. No consensus has been reached on how shame and embarrassment differ (3). Intuitively, for English speakers at least, shame and embarrassment are members of the same family and the differences between the two are subtle. The establishment of explicit differential criteria to distinguish shame from embarrassment has proven difficult in the literature. Shame is psychologically more challenging than embarrassment, marked by intensely painful negative self-evaluation commonly exhibited by an individual upon realizing that she/he has committed an offense or violated an important (usually social) norm. Shame is more long-lasting and produces more damage to self-esteem. Shame is also associated with a more serious breach of fundamental norms or rules. Upon contemplating the transgression, the individual concludes that she/he is incapable, worthless, fundamentally flawed, reprehensible, and worthy of contempt. Whereas, embarrassment is about minor transgressions or failures in role enactments or failure in one's ability to present her/himself to others in an ideal manner. Embarrassment is associated with a motivational response directed toward the preservation of one's social reputation, rather than a concern for others' well-being and a need to make amends, as in guilt, or with a concern for oneself with a need to hide as in shame (4).

Abbreviations: BDI-II, Beck Depression Inventory II; LEDD, levodopa equivalent daily dose; MDS-UPDRS motor score, motor scale of Movement Disorder Society Unified Parkinson's Disease Rating Scale; MOCA, MONTreal Cognitive Assessment; PD, Parkinson's disease; PD, phenotype: TR, tremor dominant, AR, akinetorigid form; PDQ-8, Parkinson's Disease Questionnaire 8 items (Health-related quality of life); PFQ-2, Personal Feelings Questionnaire (shame and embarrassment scale); SD, standard deviation; STAI, State-Trait Anxiety Inventory; SPARK, Shame and embarrassment in PARKinson's disease questionnaire; TPQ, Tridimensional Personality Questionnaire.

Shame and embarrassment in PD may emerge from different sources: (1) PD symptoms, especially visible motor symptoms but also non-motor symptoms; (2) increasing physical dependence and need for help induced by PD; and (3) deteriorated body image (2). Consequences of PD-related shame on health-related quality of life are probably important but have not been studied in detail. Consequently, shame and embarrassment should be actively explored and addressed in patients affected with PD.

To do so, a specific tool to detect and measure these emotions in PD is needed. We therefore created a self-applied questionnaire rating shame and embarrassment specifically induced by PD or its treatment, to promptly identify the presence and severity of these emotions in PD patients as well as to better understand what clinically promotes these emotions. The objective of this pilot study is to describe the development process of this rating scale, including its conception and the analysis of its relevance and adequateness to the target population as well as its psychometric properties.

MATERIALS AND METHODS

The study was approved by the Geneva Ethics Committee. All participants gave their informed written consent.

Identification and Selection of Items of Interest (Phase 1)

Identification of relevant items was based on a set of opinions and perspectives expressed by 44 PD patients during support groups and informal interview. The inclusion criteria for participants was a diagnosis of PD. The only exclusion criteria was the presence of dementia. The content of the expressed views was subsequently analyzed and reduced to a set of qualitative themes or meaning units. This preliminary phase of the study was from our point of view an essential component, as it allowed us to better understand shame and embarrassment related to the disease in PD patients. In addition, a comprehensive review of the literature on shame and stigmatization in PD was carried out. It revealed that the utterances expressed by patients were, generally, on the mark. Following further understanding obtained from this review process, new items were added to the emerging scale. Extra items were implemented from two scales: 2 items from the PDQ-39 (5) and 6 items from the Stigma Scale for Chronic Illness 8-item version (6). Data obtained during phase 1 provided the construction of a preliminary scale including 26 items. Responses reflected a scale of intensity (from 0 to 3: 0 = not at all, 1 = a little,

2 = moderately, 3 = very much). The scale was called Shame and embarrassment in Parkinson's disease (SPARK).

Construction of the First Draft of the Scale and Pre-testing (Phase 2)

The preliminary SPARK scale was applied to 26 patients with a diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank criteria (7). Patients were recruited from the Neurology Department of the Geneva University Hospital. PD patients with any kind of dementia (including mild and moderate) defined by a Montreal cognitive assessment (MOCA) score (8) <26/30 were excluded. A cognitive debriefing questionnaire was administered after completion of the SPARK scale, asking patients about their opinions on the relevance of the subject for their medical follow-up, length of the questionnaire, simplicity to respond, embarrassment with any item, omissions and global view. This was done to identify ambiguities, redundancies and omissions as well as to obtain preliminary data of acceptability and relevance of the subject. This questionnaire consists of 8 items with two possible answers (yes or no). A space for text where subjects could express their opinion was also available for each question.

Reformulation and Construction of the Second Version of the Scale

The preliminary scale was adapted after the analysis of the cognitive debriefing questionnaire. The new scale was reviewed by five experts in PD and four experts in questionnaire validation. A second version of the SPARK questionnaire was created, with 33 items grouped into 6 subscales: (1) Shame and embarrassment arising from PD symptoms (items 1–5, 8, 11–16, 20); (2) Shame and embarrassment arising from the increasing physical dependence and need for help induced by PD (items 7, 10, 18); (3) Shame and embarrassment arising from the deteriorated body image (items 6, 9, 17, 19, 21); (4) Consequence of related shame and embarrassment on patient's self-esteem (items 22, 25, 26); (5) Stigmatization (items 23, 24, 27–31); (6) Type of emotion (item 32 for embarrassment, item 33 for shame). A summary score was calculated by adding up all individual item scores, for a maximum of 99 points. The self-assessment SPARK questionnaire takes ~5 min to perform.

Testing of the Second Version of the Scale (Phase 3)

Thirty-five PD patients with no dementia were enrolled. A neurological assessment was performed including a brief medical history aimed to determine PD duration, stage of the disease established by Hoehn and Yahr scale (9), levodopa equivalent daily dose (LEDD) (10) and educational level, as well as a motor assessment including a MDS-UPDRS part 3 (11), the determination of the type of PD phenotype (12) and the level of dyskinesia using the Marconi Dyskinesia Rating Scale (13). The previously described SPARK debriefing questionnaire used during the pretesting phase was applied. Other questionnaires were also administered to assess psychobehavioral symptoms

such as depression using the Beck Depression Inventory II (BDI-II) (14), anxiety with the State-Trait Anxiety Inventory for Adults (STAI) (15) and apathy with the Apathy scale (16). Personality dimensions were assessed with the Tridimensional Personality questionnaire (TPQ) (17). The impact on health-related quality of life was studied with a shorter version of the Parkinson's Disease Questionnaire (PDQ)-39, called the PDQ-8 (18, 19). To compare our results with two previously validated scales exploring the propensity to feel embarrassed or ashamed, we used the Personal Feelings Questionnaire (PFQ-2) (20–22) and the Embarrassment scale (21, 23).

Construction of the Final Version of the Scale

Patients' comments provided during the debriefing questionnaire were discussed between the authors. Comments judged relevant were used to create the final version of the SPARK scale (**Figure 1** and **Supplementary Data 1**) that will be used in a future validation study.

Data Analysis

Descriptive statistics of the sample characteristics and the applied rating scales were carried out. SPARK psychometric properties were studied only in the 35 PD patients who took part in phase 3 of the study. The following psychometric properties were analyzed, following the Classical Test Theory (CTT) (24):

- Data quality and acceptability (25, 26): missing data (standard criterion: <10%), fully computable data (criterion: >90%); distribution of scores, floor and ceiling effects (criterion: <15%) and skewness (criterion: between -1 and +1).
- Reliability in terms of internal consistency (27, 28): Cronbach's alpha (standard criterion: >0.70), inter-item correlation (criterion: 0.20–0.75), item homogeneity coefficient (criterion: >0.15) and corrected item-total correlation (criterion: ≥ 0.30).
- Validity. Three aspects of validity were assessed: convergent and known-groups validity (29), internal validity and content validity. For convergent validity, Spearman rank correlation (r_s) was calculated between SPARK (total and subscale scores) and scores obtained with the two previously validated scales measuring shame and embarrassment as well as scores obtained with scales measuring depression, anxiety, apathy, type of personality and quality of life impact, constructs that theoretically should be related with the shame and embarrassment. A high correlation was established if the coefficient value r_s was ≥ 0.60 (30). A moderate to high correlation was considered if r_s was between 0.30 and 0.59. A moderate or weak was defined if r_s was <0.30. Known-group validity was tested by determining the differences in SPARK total and subscales scores with subgroups based on sex, level of education according to the International Standard Classification of Education, PD duration (by the median), Hoehn and Yahr (9) severity stage, and type of PD phenotype (using MDS-UPDRS scores and applying the formula as explained in **Supplementary Table 1**) (12). The Mann-Whitney test was utilized to determine the significance of the differences. Internal validity was assessed by

This questionnaire aims the severity of embarrassment and shame which can be experienced in people with Parkinson's disease.

For each statement, please circle the response that best to identify the presence and describes the way you have been feeling recently. Please take into account the beginning of the sentence marked in bold for each of the following questions.

I feel embarrassed or ashamed due to Parkinson's disease...

... because of my visible symptoms such as:

1. Tremor	No	A little	Moderately	A lot
2. Slowness, small writing, lack of dexterity, stiffness	No	A little	Moderately	A lot
3. Dry mouth or excess saliva	No	A little	Moderately	A lot
4. Walking, balance or postural difficulties	No	A little	Moderately	A lot
5. Jerking or involuntary movements	No	A little	Moderately	A lot
6. ... because others have an image of me that doesn't correspond to who I really am.	No	A little	Moderately	A lot
7. ... because I need to ask for help from my family or people around me.	No	A little	Moderately	A lot
8. ... because my speech difficulties (e.g., articulation, voice, rhythm, understandability) affect my ability to communicate with others.	No	A little	Moderately	A lot
9. ... because this disease is perceived to be a disease of older people.	No	A little	Moderately	A lot
10. ... because I am no longer able to do what I once did in the past.	No	A little	Moderately	A lot
11. ... because my lack of facial expression is misinterpreted as being unfriendly, odd or ill-tempered.	No	A little	Moderately	A lot

I feel embarrassed or ashamed due to Parkinson's disease...

... because of my non motor symptoms such as:

12. Modification of emotions (over sensitivity, blunting)	No	A little	Moderately	A lot
13. Problems with memory or concentration difficulties, or slow thinking	No	A little	Moderately	A lot
14. Hallucinations	No	A little	Moderately	A lot
15. Behavioral changes (e.g., gambling addiction, hypersexuality, compulsive buying, bulimia)	No	A little	Moderately	A lot
16. Reduced motivation	No	A little	Moderately	A lot

I feel embarrassed or ashamed due to Parkinson's disease...

17. ... because people think that I am more fragile than I really am.	No	A little	Moderately	A lot
18. ... because I am progressively losing my independence.	No	A little	Moderately	A lot
19. ... because my body no longer represents who I really am.	No	A little	Moderately	A lot
20. ... because of my urinary problems (urgent need to go to the toilet), stomach problems (e.g., constipation) or my sexual difficulties.	No	A little	Moderately	A lot
21. ... because I am losing control of my body.	No	A little	Moderately	A lot

Due to Parkinson's disease,

22. ... I feel useless.	No	A little	Moderately	A lot
23. ... some people seem uncomfortable around me.	No	A little	Moderately	A lot
24. ... people avoid looking at me.	No	A little	Moderately	A lot
25. ... I feel worthless.	No	A little	Moderately	A lot
26. ... I feel incompetent.	No	A little	Moderately	A lot
27. ... I avoid going out, talking in public or social encounters.	No	A little	Moderately	A lot
28. ... I feel left out of things.	No	A little	Moderately	A lot
29. ... I am not being taken seriously.	No	A little	Moderately	A lot
30. ... I feel that I have to hide my disease.	No	A little	Moderately	A lot
31. ... I feel worried by others' reaction to me.	No	A little	Moderately	A lot
32. ... I feel embarrassed.	No	A little	Moderately	A lot
33. ... I feel ashamed.	No	A little	Moderately	A lot

FIGURE 1 | The SPARK questionnaire.

means of the inter-correlation of domains, using Spearman's rank correlation coefficients (criterion, $r_s = 0.30-0.70$). For content validity, in addition to the input from experts opinion and literature review during the construction process, the qualitative evidence from the pre-testing debriefing questionnaire with patients was analyzed, to ensure that items in the scale were representative of the construct being measured (28). For the debriefing questionnaire, the frequency of yes/no responses was reported. The comments of the patients were analyzed descriptively to assess their opinions. All calculations were made using IBM SPSS version 25.0.

RESULTS

A total of 105 patients were enrolled in our study: 44 patients for phase 1, 26 for phase 2 and 35 for phase 3 of the pilot study. Demographic and clinical characteristics are reported in **Table 1**. Among the 61 patients who participated in phases 2 and 3 of the study, most patients (85%) were experiencing embarrassment, whereas shame concerned fewer patients (26%). When shame

was present, embarrassment was always associated with it. Fifteen percent of patients did not describe any shame or embarrassment.

The phase 3 of our study analyzed SPARK's psychometric properties. The SPARK total mean score was 23.97 (standard deviation SD: 18.53; range: 1–84) (**Table 2**). SPARK total score presented a skewness of 1.50, with no floor or ceiling effects (2.9% each) or missing data. Responses to items covered the full range of scale scores (0–3) except for 3 items. Most subscales and items showed a marked floor effect (**Table 2**).

Regarding internal consistency (**Table 3**), Cronbach's alpha ranged from 0.73 (Physical dependence subscale) to 0.87 (subscale Self-esteem), with a value of 0.94 for the total score. Item homogeneity coefficient ranged from 0.29 (PD symptoms subscale) to 0.70 (Self-esteem subscale). Most items (except items 1, 3 and 24) showed an item-total corrected correlation >0.40 .

SPARK total score strongly correlated with PDQ-8 ($r_s = 0.81$), PFQ-2 total and Shame subscale ($r_s = 0.66$ and 0.69 , respectively), Embarrassment scale ($r_s = 0.68$), STAI State and Trait ($r_s = 0.62$ and 0.72 , respectively) and BDI-II ($r_s = 0.63$) (**Table 4**). Moderate to high correlations were observed between SPARK total score and Apathy scale ($r_s = 0.46$) and TPQ Harm

TABLE 1 | Patients demographic and clinical characteristics for the three phases of the study.

	Numbers	Median	Range (min-max)
Pilot study 1			
Number of participants (men)	44 (15)		
Age (years)		65	60–75
Disease duration in years		5.0	2–10
Pilot study 2			
Number (men)	26 (16)		
Age (years)		64.6	39–82
Hoehn and Yahr (/4)		2	1.5–4
Motor score MDS-UPDRS III (/132)		18	5–40
MOCA (/30)		28	26–30
Pilot study 3			
Number (men)	35 (15)		
Age (years)		67	43–77
Education level (I, II, ≥III)	4 I, 12 II, 19 ≥III		
Disease duration in years		8.7	1.9–19.1
Motor score MDS-UPDRS III (/132)		17	6–54
Dyskinesia score (/28)		2	0–10
Levodopa-equivalent daily dose (mg/day)		785	100–2,100
PD phenotype	10 TR, 24 AR, 1 Mixed		
MOCA (/30)		29	26–30
Hoehn and Yahr (/4)		2	1.5–4
PDQ-8 (/32)		9	0–27
Apathy scale (Starkstein) (/42)		9	3–23
Anxiety state score (STAI) (/80)		25	20–58
Anxiety trait score (STAI) (/80)		34	23–58
Depression score (BDI-II) (/63)		9	1–28

BDI-II, Beck Depression Inventory II; Dyskinesia, Marconi Dyskinesia Rating scale; MDS-UPDRS motor score, motor scale of Movement Disorder Society Unified Parkinson's Disease Rating Scale; MOCA, MONTreal Cognitive Assessment; PD, Parkinson's disease; PD, phenotype: TR, tremor-dominant; AR, akinetic-rigid dominant; PDQ-8, Parkinson's Disease Questionnaire; Education level, Level I is defined as subjects who received a primary education, Level II a lower secondary education, and level 3 and above at least an upper secondary education.

avoidance ($r_s = 0.46$). A negative weak to moderate correlation was observed between SPARK total score and age ($r_s = -0.37$). PD duration, LEDD, motor score and type of PD phenotype showed weak to moderate correlations with SPARK. All SPARK subscales significantly correlated with PDQ-8 ($r_s \geq 0.60$). SPARK subscales PD Symptoms and Body image strongly correlated ($r_s = 0.68$ and 0.73 , respectively) with PFQ-2 Shame subscale; and PD Symptoms and Stigma strongly correlated ($r_s = 0.63$ and 0.68 , respectively) with the Embarrassment scale. PD duration, LEDD and MDS-UPDRS part 3 showed weak correlations with SPARK.

Regarding known-groups validity (Supplementary Data 2), SPARK total and subscales scores did not present significant differences by sex, education level, PD duration, Hoehn and Yahr severity stages or PD phenotype.

Regarding internal validity, SPARK subscales correlated from 0.31 to 0.74 between them (Table 5). In terms of content validity, patients' responses to the debriefing questionnaire (Table 6) demonstrated that >85% of the group found the scale to be relevant to their current situation, helpful for their healthcare professionals to understand their current state, understandable and with adequate length. Questions were described as embarrassing or difficult to answer only by 8.6 and 11.4% of the sample, respectively. Thirty-two percent of patients made comments. See Supplementary Data 3 for a summary of patients' comments. Some items were consequently modified and some subitems were added in order to capture the topic as comprehensively as possible. Comments on embarrassment and shame induced by sleep disturbances such as daytime sleepiness and acting out dreams were not included in the final version of the scale because this comment was made by a single patient.

DISCUSSION

SPARK is a new self-administered questionnaire assessing shame and embarrassment induced by PD. The aim of our study was to show how SPARK was conceived and designed. In addition, some psychometric properties have been tested to orient the developers toward potential problems with the current structure. Preliminary analyses of the psychometric properties suggest that SPARK could be an acceptable and reliable instrument for assessing shame and embarrassment in PD. Higher scores of shame and embarrassment were related to impaired health-related quality of life and higher levels of depression and anxiety. Consequently, PD-related embarrassment and shame probably deserve our attention. SPARK could be a useful tool for healthcare professionals and researchers to identify and rate these two negative emotions, as well as to better understand what clinically promotes these two painful and disruptive emotions.

Regarding the psychometric analysis, SPARK had a satisfactory acceptability and data quality with no missing data, due to good procedures during data collection. Internal consistency and internal validity were acceptable, suggesting that the scores of our instrument were an adequate reflection of the dimensionality of the construct (embarrassment and shame) that we thought to measure. Content validity was very satisfactory, with the vast majority of patients thinking that the questionnaire was relevant to their current situation and could be helpful for their healthcare professional for their follow-up. SPARK was judged by patients as easily understandable and of adequate length, taking about 5 min to complete. The content validity was excellent, probably due to the SPARK construction and testing process which involved a collaborative effort with multiple exchanges between PD patients and healthcare professionals specialized in PD.

In terms of the frequency of shame and embarrassment induced by PD, most of our patients (85%) were experiencing embarrassment whereas shame concerned far fewer patients (26%). When shame was present, it was associated with embarrassment in 100% of cases. Our results argue for the fact that embarrassment and shame are two closely related

TABLE 2 | Data quality and acceptability of SPARK.

	N	Mean	Median	SD	Skewness	Min	Max	Floor effect %	Ceiling effect %
Item SPARK1	35	0.89	1.00	0.90	0.49	0	3	42.90	2.90
Item SPARK2	35	1.26	1.00	0.98	0.44	0	3	22.90	14.30
Item SPARK3	35	0.46	0.00	0.74	1.76	0	3	65.70	2.90
Item SPARK4	35	1.09	1.00	1.07	0.59	0	3	37.10	14.30
Item SPARK5	35	0.86	0.00	1.11	0.97	0	3	54.30	14.30
Item SPARK 6	35	0.94	1.00	0.97	0.74	0	3	40.00	8.60
Item SPARK 7	35	0.60	0.00	0.81	1.23	0	3	57.10	2.90
Item SPARK 8	35	0.69	0.00	0.90	1.20	0	3	54.30	5.70
Item SPARK 9	35	0.74	0.00	1.12	1.21	0	3	62.90	14.30
Item SPARK 10	35	1.34	1.00	1.16	0.23	0	3	31.40	22.90
Item SPARK 11	35	0.86	0.00	1.11	0.97	0	3	54.30	14.30
Item SPARK 12	35	0.89	1.00	0.99	1.00	0	3	42.90	11.40
Item SPARK 13	35	0.77	1.00	0.91	1.23	0	3	45.70	8.60
Item SPARK 14	35	0.06	0.00	0.24	3.99	0	1	94.30	5.70
Item SPARK 15	35	0.46	0.00	0.92	1.82	0	3	77.10	5.70
Item SPARK 16	35	0.69	0.00	1.02	1.39	0	3	60.00	11.40
Item SPARK 17	35	0.60	0.00	0.91	1.65	0	3	60.00	8.60
Item SPARK 18	35	0.94	1.00	1.11	0.80	0	3	48.60	14.30
Item SPARK 19	35	0.86	1.00	0.97	1.11	0	3	42.90	11.40
Item SPARK 20	35	1.06	1.00	1.16	0.60	0	3	45.70	17.10
Item SPARK 21	35	0.77	0.00	0.97	0.90	0	3	54.30	5.70
Item SPARK 22	35	0.51	0.00	0.89	1.97	0	3	65.70	8.60
Item SPARK 23	35	0.40	0.00	0.60	1.26	0	2	65.70	5.70
Item SPARK 24	35	0.09	0.00	0.28	3.09	0	1	91.40	8.60
Item SPARK 25	35	0.34	0.00	0.84	2.44	0	3	82.90	5.70
Item SPARK 26	35	0.63	0.00	0.97	1.65	0	3	60.00	11.40
Item SPARK 27	35	1.00	1.00	1.16	0.71	0	3	48.60	17.10
Item SPARK 28	35	0.54	0.00	0.85	1.37	0	3	65.70	2.90
Item SPARK 29	35	0.29	0.00	0.67	2.75	0	3	80.00	2.90
Item SPARK 30	35	0.77	0.00	1.06	1.12	0	3	57.10	11.40
Item SPARK 31	35	0.71	0.00	1.07	1.22	0	3	62.90	11.40
Item SPARK 32	35	1.34	1.00	0.87	0.37	0	3	14.30	11.40
Embarrassment									
Item SPARK 33 Shame	35	0.54	0.00	0.95	1.72	0	3	68.60	8.60
Subscale SPARK	35	10.00	9.00	7.21	1.34	1	30	5.70	2.90
PD symptoms									
Subscale SPARK	35	3.91	3.00	3.84	0.66	0	9	25.70	2.90
Physical dependence									
Subscale SPARK	35	2.89	3.00	2.52	1.32	0	15	17.10	2.90
Body image deterioration									
Subscale SPARK	35	1.49	1.00	2.42	2.17	0	9	48.60	5.70
Self-esteem									
Subscale SPARK	35	3.80	3.00	3.94	0.96	0	15	28.60	2.90
Stigmatization									
SPARK Total (/99)	35	23.97	19.00	18.53	1.50	1	84	2.90	2.90

N, number of items in the questionnaire; *SD*, standard deviation.

self-conscious emotions belonging to the same continuum of emotion, varying on a range of factors such as intensity, public exposure and physical reaction (31). To the best of our knowledge, the exact prevalence of the shame and

embarrassment in PD is unknown and our percentages would have to be checked in a larger sample. Parkinson's UK, a patients' association, found that 41% of PD patients reported experiencing discrimination because of PD, including some

experiences of misinterpretation of symptoms or verbal abuse in public (32).

In terms of the intensity of shame and embarrassment, SPARK total score had a mean of 24 out of 99 with a wide range of scores (1–84) showing that the severity of the shame and embarrassment varied greatly among patients. Floor effect in SPARK items and subscales indicated that most patients showed low levels of shame and embarrassment. However, SPARK scores were associated with a lower level of health-related quality of life, as well as with higher levels of depression and anxiety. Shame and embarrassment may contribute to psychological difficulties such as personal distress, self-identity alteration, social isolation,

depression, and social anxiety (33–36). The impact of shame and embarrassment on patients' quality of life might be exacerbated by the fact that patients do not talk about this feeling because it is a taboo subject (37). Many PD patients do not spontaneously discuss these experiences with their relatives or their neurologist because, ironically, they think that it is considered embarrassing or shameful to talk about one's embarrassment or the sources of one's shame (2).

The wide range of SPARK scores among patients probably reflects the inter-individual variability of the experience of shame and embarrassment. These two emotions vary depending on self-awareness, personality traits, level of self-esteem and self-blame, and culture (38–41). Our results are in accordance with this assumption, whereby higher SPARK scores were related to the personality propensity to feel embarrassed or ashamed and with a personality trait directed toward harm avoidance.

The role of PD neuropathology itself in the experience of shame and embarrassment is unknown. According to our study, an indirect and a direct role of PD are probable. An indirect role is probable through symptoms caused by PD as well as the increasing physical dependence and the deteriorated body image. However, a direct role of PD on the emotional experience might also be associated, but remains to be demonstrated. PD is secondary to neurodegeneration involving predominantly dopaminergic neurons (42). Higher

TABLE 3 | Internal consistency of SPARK.

Subscales	Item-total corrected correlation	Cronbach's Alpha	Inter-item correlation	Item homogeneity
PD symptoms	0.01–0.71	0.84	–0.36–0.73	0.29
Physical dependence	0.44–0.71	0.73	0.30–0.63	0.47
Body image	0.58–0.71	0.83	0.41–0.80	0.50
Self-esteem	0.71–0.85	0.87	0.59–0.77	0.70
Stigmatization	0.05–0.62	0.77	–0.13–0.70	0.32

TABLE 4 | Convergent validity of SPARK scale and subscales.

	PD Symptoms	Physical dependence	Body image	Self- esteem	Stigma	Item 32 Embarr.	Item 33 Shame	SPARK TOTAL
Age	–0.33	–0.27	–0.19	–0.23	–0.36*	–0.34*	–0.45**	–0.37*
Duration of PD	0.20	–0.09	0.22	–0.03	0.03	–0.13	–0.33	0.10
LEDD	0.27	–0.03	0.18	0.00	0.08	–0.12	0.04	0.11
MOCA	–0.23	–0.20	–0.22	–0.03	0.15	–0.00	0.31	–0.14
MDS-UPDRS 3	0.03	0.05	0.13	0.10	0.16	0.09	–0.02	0.10
Tremor score	–0.31	0.12	–0.14	–0.09	–0.32	–0.02	–0.05	–0.21
Akinetic-rigid score	0.19	0.06	0.22	0.20	0.31	0.08	0.02	0.23
PIGD score	–0.12	–0.01	0.06	–0.17	–0.20	–0.15	–0.28	–0.09
Apathy scale	0.39*	0.29	0.26	0.59**	0.45**	0.22	0.25	0.46**
PDQ-8 total	0.75**	0.64**	0.68**	0.60**	0.69**	0.47**	0.41*	0.81**
PFQ-2 total	0.62**	0.50**	0.63**	0.42*	0.53**	0.41*	0.40*	0.66**
PFQ-2 shame	0.68**	0.54**	0.73**	0.43*	0.52**	0.41*	0.26	0.69**
PFQ-2 guilt	0.40*	0.37*	0.36*	0.32	0.43*	0.34*	0.51**	0.47**
Embarrassment scale	0.63**	0.46**	0.59**	0.54**	0.68**	0.38*	0.22	0.68**
TPQ novelty seeking	0.32	0.15	0.32	0.11	0.21	–0.10	0.06	0.29
TPQ Harm avoidance	0.37*	0.44**	0.38*	0.60**	0.36*	0.20	0.24	0.46**
TPQ reward dependence	0.22	0.36*	0.28	0.14	–0.10	0.09	0.06	0.25
STAI state	0.55**	0.53**	0.43*	0.62**	0.46**	0.28	0.39*	0.62**
STAI trait	0.57**	0.64**	0.59**	0.61**	0.64**	0.48**	0.36*	0.72**
BDI-II total	0.56**	0.53**	0.43**	0.48**	0.52**	0.35*	0.47**	0.63**

Scores are expressed using Spearman rank correlation coefficient value (r_s). A score $r_s \geq 0.60$ is considered to have a high correlation level. A score between 0.30 and 0.59 is considered to have a moderate to high correlation level. A score < 0.30 is considered to have a moderate to weak correlation level.

* $p < 0.05$; ** $p < 0.01$. p refers to the significance level of the correlation coefficients.

BDI-II, Beck Depression Inventory II; Embarr, embarrassment; LEDD, levodopa equivalent daily dose; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; MOCA, Montreal Cognitive Assessment; PD, Parkinson's disease; PDQ-8, Parkinson's Disease Questionnaire (Health-related quality of life), 8 items; PFQ-2, Personal Feelings Questionnaire (shame and embarrassment scale); TPQ, Tridimensional Personality Questionnaire; STAI, State-Trait Anxiety Inventory.

TABLE 5 | Internal validity.

	PD symptoms	Physical dependence	Body image	Self Esteem	Stigma	Item 32 embarrassment
Physical dependence	0.59**					
Body image	0.71**	0.74**				
Self Esteem	0.60**	0.56**	0.49**			
STIGMA	0.61**	0.47**	0.59**	0.70**		
Item 32 Embarrassment	0.38*	0.58**	0.47**	0.45**	0.57**	
Item 33 Shame	0.48**	0.34*	0.31	0.43**	0.53**	0.48**

Standard: $r_S > 0.50$; * $p < 0.05$; ** $p < 0.01$.

TABLE 6 | Responses to the debriefing questionnaire about SPARK.

	Answer	N	%
Relevance for the patient's current situation	No	5	14.3
	Yes	30	85.7
Helpfulness for their healthcare professionals to understand the patient's current situation	No	1	2.9
	Yes	34	97.1
Good understandability	No	0	0.0
	Yes	35	100.0
Missing aspects	No	24	68.6
	Yes	11	31.4
Length	No	34	97.1
	Yes	1	2.9
Embarrassing questions	No	32	91.4
	Yes	3	8.6
Difficulty to answer questions	No	31	88.6
	Yes	4	11.4
Comments	No	22	62.9
	Yes	13	37.1

N, number of patients.

SPARK scores were related to a more pronounced personality variant toward harm avoidance, whereas SPARK scores were not linked with the two other personality dimensions defined by Cloninger's biosocial model of personality (novelty seeking and reward dependence) (43). The harm avoidance dimension is characterized by a tendency to respond intensely to signals of aversive stimuli, thereby learning to inhibit behavior to avoid punishment, novelty and frustrative non rewarding situations. Individuals with higher levels of harm avoidance show anticipatory worry, fear of uncertainty, shyness with strangers as well as fatigability and asthenia. Yet harm avoidance has been linked with hypodopaminergic behaviors such as apathy, depression, anxiety, irritability, and hyperemotionality (44–46) as well as with PD (47). In addition, SPARK scores were strongly related with higher levels of depression and anxiety, and moderately associated with the level of apathy. We hypothesized

a dopaminergic modulation to embarrassment and shame in PD. We expect that shame and embarrassment would decrease in the case of hyperdopaminergia (euphoria, hyperactivity, hypomania, and impulse control disorders) when also depression, anxiety, apathy and harm avoidance largely disappear. This assumption remains to be elucidated.

No relationship was found between the intensity of PD-induced shame and embarrassment and PD duration and the severity of motor symptoms. These results might suggest that other factors might be involved in the intensity of the shame and embarrassment. A longitudinal study investigating the evolution of SPARK scores depending on the phase of PD would be interesting. Our hypothesis is that the intensity of shame and embarrassment might be higher before the dopaminergic replacement therapy is introduced and during the early post-diagnosis phase when the patient is learning to adapt to her/his disease. Another hypothesis would be that shame and embarrassment are little related with motor symptoms as compared with neuropsychiatric symptoms.

Nevertheless, our scale contains several limitations. Three items presented low item-total corrected correlations with their respective subscales. Two pairs of items showed high inter-item correlation which might suggest redundancy. This aspect will be checked during the validation study in a larger sample. As pointed out by the debriefing questionnaire, some aspects contributing to shame and embarrassment were missing. Some new items were consequently added (stiffness, dysarthria, dry mouth, posture difficulties) in order to capture the topic as comprehensively as possible. The final version of SPARK will be utilized during the future validation study. As mentioned by several patients and because of the type of rating scale that we chose, SPARK measures the intensity of shame and embarrassment but not the frequency of the occurrence of these two emotions. SPARK also does not differentiate clearly if shame and embarrassment are internal or external. Internal shame or embarrassment describes the negative evaluation a person applied to her/himself whereas external shame or embarrassment relates to the evaluation of what the person believes others think about her/him i.e. the distressing awareness that "I think others view me negatively" (48). The amount of psychosocial support received by patients was not able to be measured. It is however data that may well influence PD-induced shame and embarrassment and in this sense, should be taken into account

in future studies. Finally, SPARK could encounter difficulties at a linguistic level in non-English or non-French speaking countries. Indeed, the distinction between shame and embarrassment may not be obvious depending on the language. In Spanish for example, the distinction between shame and embarrassment does not exist in the common (everyday life) language. For this reason, we chose to combine embarrassment and shame as a single combined score. Future studies should also address the role of culture on shame and embarrassment in PD. How emotions are understood and expressed varies across cultures (40, 41). Some social groups view the self in individualistic psychological terms as a self that is bounded, separate from others. Shame and embarrassment are then perceived as a psychological event occurring inside an individual. Meanwhile, other cultures favor a collectivist conception wherein shame and embarrassment are emotions that happen interpersonally, outside, between people (39). The appraisal of how shame and embarrassment are felt and expressed, as well as the responsibility for resolving them, also varies (38). International studies are needed, with a more diverse sample of PD patients in order to explore cultural differences regarding the embarrassment and shame by a formal study. Finally, our sample size was relatively small.

In conclusion, the SPARK scale could be a reliable questionnaire which promptly measures the severity of shame and embarrassment specifically induced in patients in the context of PD. A validation study would be useful to confirm this assumption. The availability of this rating scale could raise awareness on these two emotions in PD. The SPARK scale could help healthcare professionals to identify the problem of shame and embarrassment affecting PD patients and to better understand what clinically promotes these two emotions. Our study demonstrated that PD-associated embarrassment is extremely frequent. Shame and embarrassment were associated with a lower level of health-related quality of life, as well as with higher levels of depression and anxiety. As such, PD-related shame and embarrassment deserve our attention. Further studies are needed to deepen the understanding of the subject, such as studies exploring clinical, cultural or socioeconomic factors influencing these two painful emotions. The clinical implication of this score system could be important especially in patients who score high on SPARK total score and shame sub-item as shame probably contributes to psychological difficulties such as personal distress, depression, suicidal ideation, and social encounter avoidance. A high SPARK score should alert healthcare professionals to the potential presence of psychological difficulties. The SPARK questionnaire could therefore help healthcare professionals

to implement psychological support to patients' management in a timely fashion in order to help patients cope with their disease. Cognitive-behavioral intervention strategies such as systematic desensitization, role playing, thought stopping, disputing the inner critic, identification of irrational thinking and dysfunctional cognitive schemas could be clinically beneficial for these 2 emotions (49, 50). The SPARK scale could also help indirectly researchers to better understand the biological role of monoaminergic neurotransmitter depletion in these negative emotions. Understanding the biology behind shame and embarrassment could allow more targeted pharmacological management in addition to enhancing coping strategies.

DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/**Supplementary Material**.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Geneva Ethics Committee (SwissEthics). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

VF, SC, MF, MM, ID, G-MH, PM-M, CR-B, and PK: conception and design of the study. VF, SC, MF, MM, JA, PB, and CR-B: acquisition and analysis of data. VF, SC, MF, MD, MM, ID, G-MH, JA, PB, PM-M, CR-B, and PK: writing and review of the text and preparing tables and figures. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to thank Dr. Daniel Weintraub and Thierry Lecerf for their input during the construction of SPARK. We thank Dr. Michael Nissen for his assistance with the proofreading.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2020.00779/full#supplementary-material>

REFERENCES

- Muller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early parkinson's disease parkinsonism. *Relat Disord.* (2013) 19:1027–32. doi: 10.1016/j.parkreldis.2013.07.010
- Angulo J, Fleury V, Péron JA, Penzenstadler L, Zullino D, Krack P. Shame in Parkinson's disease: a review. *J Parkinson's Dis.* (2019) 9:489–99. doi: 10.3233/JPD-181462
- Crozier WR. Differentiating shame from embarrassment. *Emotion Rev.* (2014) 6:269–76. doi: 10.1177/1754073914523800

4. Tangney JP, Miller RS, Flicker L, Barlow DH. Are shame, guilt, and embarrassment distinct emotions? *J Pers Soc Psychol.* (1996) 70:1256–69. doi: 10.1037/0022-3514.70.6.1256
5. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. *Qual Life Res.* (1995) 4:241–8. doi: 10.1007/BF02260863
6. Molina Y, Choi SW, Cella D, Rao D. The stigma scale for chronic illnesses 8-item version. (SSCI-8): development, validation and use across neurological conditions. *Int J Behav Med.* (2013) 20:450–60. doi: 10.1007/s12529-012-9243-4
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* (1992) 55:181–4. doi: 10.1136/jnnp.55.3.181
8. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* (2005) 53:695–9. doi: 10.1111/j.1532-5415.2005.53221.x
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology.* (1967) 17:427–42. doi: 10.1212/WNL.17.5.427
10. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord.* (2010) 25:2649–53. doi: 10.1002/mds.23429
11. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord.* (2008) 23:2129–70. doi: 10.1002/mds.22340
12. Pagano G, Ferrara N, Brooks DJ, Pavese N. Age at onset and Parkinson disease phenotype. *Neurology.* (2016) 86:1400–7. doi: 10.1212/WNL.0000000000002461
13. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. *Mov Disord.* (1994) 9:2–12. doi: 10.1002/mds.870090103
14. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. *J Pers Assess.* (1996) 67:588–97. doi: 10.1207/s15327752jpa6703_13
15. Spielberger CD. *Manual for the State-Trait Anxiety Inventory.* Palo Alto, CA: Consulting Psychologists Press (1983).
16. Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B. The syndromal validity and nosological position of apathy in Parkinson's disease. *Mov Disord.* (2009) 24:1211–6. doi: 10.1002/mds.22577
17. Cloninger CR, Przybeck TR, Svrakic DM. The tridimensional personality questionnaire: U.S. normative data. *Psychol Rep.* (1991) 69(3 Pt 1):1047–57. doi: 10.2466/pr0.1991.69.3.1047
18. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. *Psychology and Health.* (1997) 12:805–14. doi: 10.1080/08870449708406741
19. Jenkinson C, Fitzpatrick R. Cross-cultural evaluation of the short form 8-item parkinson's disease questionnaire (PDQ-8): results from America, Canada, Japan, Italy and Spain. *Parkinsonism Relat Disord.* (2007) 13:22–8. doi: 10.1016/j.parkreldis.2006.06.006
20. Harder DH, Zalma A. Two promising shame and guilt scales: a construct validity comparison. *J Pers Assess.* (1990) 55:729–45. doi: 10.1207/s15327752jpa5503andamp;4_30
21. Kelly KM, Jones WH. Assessment of dispositional embarrassability. *Anxiety Stress Coping.* (1997) 10:307–33. doi: 10.1080/10615809708249306
22. Nugier A, Gil S, Chekroun P. Validation of the French version of the Test of self-conscious affect-3. (TOSCA-3): a measure for the tendencies to feel ashamed and guilty. *Eur Rev Appl Psychol.* (2012) 62:19–27. doi: 10.1016/j.erap.2011.09.004
23. Maltby J, Day L. The reliability and validity of a susceptibility to embarrassment scale among adults. *Personal Individual Diff.* (2000) 29:749–56. doi: 10.1016/S0191-8869(99)00229-9
24. Nunnally JC, Bernstein IH. *Psychometric Theory.* New York, NY: McGraw-Hill (1994).
25. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. *Qual Life Res.* (1993) 2:441–9. doi: 10.1007/BF00422218
26. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? *Qual Life Res.* (1995) 4:293–307. doi: 10.1007/BF01593882
27. Clark LA, Watson D. Constructing validity: basic issues in objective scale development. *Psychol Assessment.* (1995) 7:309–19. doi: 10.1037/1040-3590.7.3.309
28. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument. (DEMQUAL) and an evaluation of current methodology. *Health Technol Assess.* (2005) 9:1–93. doi: 10.3310/hta9100
29. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. *J Clin Epidemiol.* (2010) 63:737–45. doi: 10.1016/j.jclinepi.2010.02.006
30. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. *J Neurol Neurosurg Psychiatry.* (2005) 76:58–63. doi: 10.1136/jnnp.2003.017897
31. Kaufman G. *The Psychology of Shame: Theory and Treatment of Shame-Based Syndromes.* 2nd ed. Springer Publishing Co. (1996).
32. UK PS. *People with Parkinson's Subject to "intolerable" Discrimination and Prejudice.* Available online at: <http://forum.parkinsons.org.uk/aboutus/mediacentre/pressreleasepaw2013.aspx> (2013).
33. Harder DW, Cutler L, Rockart L. Assessment of shame and guilt and their relationships to psychopathology. *J Pers Assess.* (1992) 59:584–604. doi: 10.1207/s15327752jpa5903_12
34. Cheung MSP, Gilbert P, Irons C. An exploration of shame, social rank and rumination in relation to depression. *Personal Individ Diff.* (2004) 36:1143–53. doi: 10.1016/S0191-8869(03)00206-X
35. Simpson J, McMillan H, Reeve D. Reformulating psychological difficulties in people with Parkinson's disease: the potential of a social relational approach to disability. *Parkinsons Dis.* (2013) 2013:608562. doi: 10.1155/2013/608562
36. Lewis DS, Anderson KH, Feuchtinger J. Suicide prevention in neurology patients: evidence to guide practice. *J Neurosci Nurs.* (2014) 46:241–8. doi: 10.1097/JNN.0000000000000062
37. Brown B. *I Thought It Was Just Me (But It Isn't): Telling the Truth about Perfectionism, Inadequacy and Power.* New York, NY: Gotham Books; Penguin (2007).
38. Kitayama S, Markus HR, Kurokawa M. Culture, emotion, and well-being: good feelings in Japan and the United States. *Cogn Emotion.* (2000) 14:93–124. doi: 10.1080/026999300379003
39. Mesquita B. Emotions in collectivist and individualist contexts. *J Pers Soc Psychol.* (2001) 80:68–74. doi: 10.1037/0022-3514.80.1.68
40. Boiger M, Mesquita B, Tsai AY, Markus H. Influencing and adjusting in daily emotional situations: a comparison of European and Asian American action styles. *Cogn Emot.* (2012) 26:332–40. doi: 10.1080/02699931.2011.572422
41. Boiger M, Gungor D, Karasawa M, Mesquita B. Defending honour, keeping face: Interpersonal affordances of anger and shame in Turkey and Japan. *Cogn Emot.* (2014) 28:1255–69. doi: 10.1080/02699931.2014.881324
42. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. *Nat Rev Dis Primers.* (2017) 3:17013. doi: 10.1038/nrdp.2017.13
43. Cloninger R. A systematic method for clinical description and classification of personality variants. A proposal. *Arch Gen Psychiatry.* (1987) 44:573–88. doi: 10.1001/archpsyc.1987.01800180093014
44. Ardouin C, Chereau I, Llorca PM, Lhommee E, Durif F, Pollak P, et al. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's

- disease]. *Rev Neurol.* (2009) 165:845–56. doi: 10.1016/j.neurol.2009.06.003
45. Kim JH, Son YD, Kim HK, Lee SY, Cho SE, Kim YB, et al. Association of harm avoidance with dopamine D2/3 receptor availability in striatal subdivisions: a high resolution PET study. *Biol Psychol.* (2011) 87:164–7. doi: 10.1016/j.biopsycho.2011.02.011
 46. Lhomme E, Boyer F, Wack M, Pelissier P, Klinger H, Schmitt E, et al. Personality, dopamine, and parkinson's disease: insights from subthalamic stimulation. *Mov Disord.* (2017) 32:1191–200. doi: 10.1002/mds.27065
 47. Santangelo G, Garramone F, Baiano C, D'Iorio A, Piscopo F, Raimo S, et al. Personality and Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord.* (2018) 49:67–74. doi: 10.1016/j.parkreldis.2018.01.013
 48. Gilbert P, Procter S. Compassionate mind training for people with high shame and self-criticism: Overview and pilot study of a group therapy approach. *Clin Psychol Psychother.* (2006) 13:353–79. doi: 10.1002/cpp.507
 49. Brown B. *Connections: A 12-Session Psychoeducational Shame-Resilience Curriculum.* Center City, MN : Hazelden (2009).
 50. Gilbert P. Introducing compassion-focused therapy. *Adv Psychiatr Treat.* (2009) 15:199–208. doi: 10.1192/apt.bp.107.005264

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Fleury, Catalano Chiuvé, Forjaz, Di Marco, Messe, Debove, Angulo, Hariz, Burkhard, Martinez-Martin, Rodriguez-Blazquez and Krack. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.